triumph-1 trial retatrutide Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH r

A new weight loss medication has produced the highest weight loss results seen in a Phase 3 obesity trial to date. The results from the TRIUMPH-1 trial, reported by this week by

22.82

★★★★☆4.8 (126)

Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials - Giblin - 2026 - Diabetes, Obesity and Metabolism

25.38

★★★★★4.9 (98)

Breaking: New Retatrutide trial data just released. TRIUMPH-1 study results on the triple agonist. Eli Lilly's clinical trial on Retatrutide (triple agonist compound). 80 weeks. Phase 3 data. The results: At 12mg

25.77

★★★★★5.0 (157)

Eli Lilly's New Weight-Loss Treatment Shows Promising Results!! Retatrutide, designed to be taken once a week, met the primary endpoint in a phase 3 clinical. The initial TRIUMPH Phase 3 clinical development

27.15

★★★★★4.7 (84)

Retatrutide TRIUMPH-1 Results: 28% Weight Loss — Is This the End of Obesity?

22.18

★★★★★4.9 (203)

Retatrutide TRIUMPH-1 Mystery Revealed

29.33

★★★★★5.0 (176)

Today we shared new results on retatrutide, an investigational, first-of-its-kind treatment we're studying in adults with obesity or overweight with at least one weight-related comorbidity. Read more about the Phase 3 findings:

23.41

★★★★★4.8 (132)